Y0000685
Letrozole
European Pharmacopoeia (EP) Reference Standard
Manufacturer: Sigma Aldrich
CAS Number: 112809-51-5
Synonym(S): 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 80 MG | Y0000685-80-MG | In Stock | ₹ 14,267.35 |
Y0000685 - 80 MG
In Stock
Quantity
1
Base Price: ₹ 14,267.35
GST (18%): ₹ 2,568.123
Total Price: ₹ 16,835.473
grade
pharmaceutical primary standard
API family
letrozole
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
InChI
1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChI key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
Gene Information
human ... CYP19A1(1588)
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
Letrozole Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™ | -- | ₹ 14,124.30 | ||
Sigma Aldrich Fine Chemicals Biosciences Letrozole United States Pharmacopeia (USP) Reference Standard | 112809-51-5 | MFCD00866241 | 200MG | -- | ₹ 47,632.80 | ||
Letrozole | -- | ₹ 11,907.50 | ||
Letrozole | -- | ₹ 24,962.45 | ||
112809-51-5 | 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile | -- | ₹ 3,560.00 - ₹ 95,586.00 |
Related Products
Description
- General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
- Application: Letrozole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
- Biochem/physiol Actions: Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.
- Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
- Other Notes: Sales restrictions may apply.
SAFETY INFORMATION
Pictograms
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Repr. 2 - STOT RE 2
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable